Arsenal Biosciences (ArsenalBio) has dosed the first subject in a Phase I/II clinical trial of AB-2100, a new therapy for treating patients with clear-cell renal cell carcinoma (ccRCC).
The multicentre, open-label, dose escalation study aims to evaluate the safety and efficacy of the treatment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ccRCC patients who have either relapsed or failed to respond to prior treatments with a checkpoint inhibitor and a VEGF inhibitor, will be part of the trial.
The trial’s primary objective is to identify the maximum tolerated dose of AB-2100, delivered intravenously as a single infusion after the patient has undergone conditioning chemotherapy.
Arsenal aims to enrol up to 60 patients in the Phase I portion and a total of 130 patients across various US clinical sites.
AB-2100 is based on ArsenalBio’s CRISPR Integration of Transgenes by Electroporation (CITE) technology that enables the engineering of T cells to selectively target the tumour while avoiding damage to normal tissues.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe asset is second internally discovered T cell therapeutic candidate of the company to enter clinics.
Apart from the ccRCC trial, an open-label, multicentre, Phase I dose escalation study of another asset, AB-1015, is under investigation for ovarian cancer treatment.
ArsenalBio chief medical officer Susie Jun said: “As with our AB-1015 programme in ovarian cancer, we hope this study succeeds in identifying a safe and therapeutic dose to enable further study of this potential therapy in larger patient cohorts.
“Based upon our preclinical data we believe this synthetic biology-based logic gate approach will enable targeting of antigens like CA9 where conventional CAR T-cell strategies have been limited by on-target toxicity in healthy tissues.”
